Advances in Brief Deletion of Chromosome 17 p Loci in Breast Cancer Cells Detected by Fluorescence in Situ Hybridization 1

Alleile loss of tumor suppressor genes on chromosome 17p has been implicated in the progression of breast cancer. This is in principle detectable by fluorescence in situ hybridization if the loss occurs by deletion. In order to determine if detectable deletions occur in primary breast cancer, we used dual-color hybridization with chromosome 17 pericentromeric and region-specific DNA probes to study 19 primary breast cancers. The copy numbers of 17 centromere and 17pl3.1 se quences were compared with the loss of heterozygosity (LOH) for probe YNZ22 at 17p13.3 detected by restriction fragment length polymorphism. Nine of 11 cases showing LOH also showed the major population of nuclei with a deletion. The remaining two tumors with LOH were trisomie for both the centromere and 17pl3.1 cosmid. In contrast, seven of eight tumors without LOH had no deletions by fluorescence in situ hybridi zation. These data suggest that the dominant mechanism of allelic loss at 17p in breast cancer is a physical deletion and that analysis of deletions by fluorescence in situ hybridization is a rapid and sensitive approach to studying chromosomal aberrations.

[1]  B H Mayall,et al.  Centromeric copy number of chromosome 7 is strongly correlated with tumor grade and labeling index in human bladder cancer. , 1991, Cancer research.

[2]  B. Ljung,et al.  Loss of heterozygosity on the short arm of chromosome 17 is associated with high proliferative capacity and DNA aneuploidy in primary human breast cancer. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[3]  F. Ramaekers,et al.  Numerical chromosome 1, 7, 9, and 11 aberrations in bladder cancer detected by in situ hybridization. , 1991, Cancer research.

[4]  D. Slamon,et al.  Frequency and structure of p53 rearrangements in human osteosarcoma. , 1990, Cancer research.

[5]  D Pinkel,et al.  Detection of bcr-abl fusion in chronic myelogeneous leukemia by in situ hybridization , 1990, Science.

[6]  D Pinkel,et al.  Detection of aneuploidy and aneuploidy-inducing agents in human lymphocytes using fluorescence in situ hybridization with chromosome-specific DNA probes. , 1990, Mutation research.

[7]  R. Lidereau,et al.  Loss of heterozygosity on chromosomes 17 and 18 in breast carcinoma: two additional regions identified. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[8]  C. M. Steel,et al.  Evidence implicating at least two genes on chromosome 17p in breast carcinogenesis , 1990, The Lancet.

[9]  W. Cavenee,et al.  Mechanisms of p53 loss in human sarcomas. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[10]  P. Devilee,et al.  Loss of heterozygosity on 17p in human breast carcinomas: defining the smallest common region of deletion. , 1990, Cytogenetics and cell genetics.

[11]  D. Ledbetter,et al.  Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. , 1989, Science.

[12]  A. Forrest,et al.  ALLELE LOSS ON SHORT ARM OF CHROMOSOME 17 IN BREAST CANCERS , 1988, The Lancet.

[13]  D. Pinkel,et al.  Fluorescence in situ hybridization with human chromosome-specific libraries: detection of trisomy 21 and translocations of chromosome 4. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[14]  S. Dairkee,et al.  Immortalization in culture: occurrence at a late stage in the progression of breast cancer. , 1987, Journal of the National Cancer Institute.

[15]  I W Taylor,et al.  Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. , 1983, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.